Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, will present the Phase II results of its drug candidate THN102 for Parkinson’s disease at the International Congress of Parkinson’s Disease and Movement Disorders, due to take place from 12 to 16 September 2020.

Complete press release Theranexus